SONN Sonnet BioTherapeutics Holdings Inc. Kompaniyaning sof daromadi

Sonnet BioTherapeutics (SONN) korporativ emblemasi va logotipi

Muntazam naqd pul oqimlarining yo'qligi biznesni beqaror qiladi, chunki rivojlanish faqat tashqi investitsiyalarga bog'liq. Biroq, mualliflikka tegishli FHAB texnologiyasi immuno-onkologik agentlarning samaradorligini oshirish orqali sezilarli texnologik to'siqni yaratadi. GURU.Markets terminal grafigida Sonnet BioTherapeutics (SONN) kompaniyasining R&D loyihalari bo'yicha sof foyda hajmini tahlil qilib, so'nggi parametr -0.01 ekanligini qayd etamiz.

SONN sonnetbio.com: Sof daromad 04.07.2022 - 13.12.2025 oraligʻida

sonnetbio.com (SONN) moliyaviy va bozor koʻrsatkichlari kesimi

- aksiya narxi va baholash bo'yicha konsensus prognoz:
Narx grafigi Sonnet BioTherapeutics Holdings|SONN - Maqsadli narxlar grafigi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Sonnet BioTherapeutics Holdings Inc.|SONN - Korxona qiymati
- balans bo'yicha xususiy kapital ma'lumotlari:
Yagona aksiya balans qiymati Sonnet BioTherapeutics|SONN - Kompaniyaning sof aktivlari|Bozor qiymatining balans qiymatiga koeffitsiyenti sonnetbio.com|SONN - Kompaniyaning yakuniy aktivlari
- qarz yuki va likvidlik ko'rsatkichlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati Sonnet BioTherapeutics|SONN - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga koeffitsiyenti Sonnet BioTherapeutics Holdings|SONN - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Sonnet BioTherapeutics Holdings Inc.|SONN - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli majburiyatlari Sonnet BioTherapeutics|Tezkor likvidlik koeffitsiyenti sonnetbio.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
SONN - Kompaniyaning sof foydasi
Kompaniyaning asosiy tahlili:SONN, Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc. tomonidan chiqariladigan mahsulotlar

Sonnet BioTherapeutics foydasi barcha operatsion va qarz majburiyatlari chegirib tashlanganidan keyingi sof moliyaviy natijani o'lchaydi va resurslarni boshqarish samaradorligining real vaqt rejimini aks ettiradi. Kompaniyaning foydasini tahlil qilish orqali investor ishchi kuchini optimallashtirish va aksiyalar opsionlari orqali immuno-onkologiya ekspertlarini saqlab qolish xarajatlarni kamaytirishga qanday hissa qo'shishini ko'rishi mumkin, bu esa Sonnet BioTherapeutics barqarorligining uzoq muddatli istiqbolini belgilaydi.

Asosiy raqobatchilar

IBRX (NantKwest) - Kompaniyaning sof foydasi|Kompaniyaning sof foydasi Immunocore Holdings plc|Kompaniyaning sof daromadi januxrx.com JANX|Sof foyda RCUS|Zymeworks Inc (ZYME) - Yillik sof foyda|Tango Pharma - Sof daromad|Iovance Corp (IOVA) - Kompaniyaning sof daromadi|IMTX: Sof daromad|Yakuniy foyda XNCR (xencor.com)|CMPX: Sof foyda|REPL - Sof moliyaviy natija|Kompaniyaning sof foydasi Lyell Immunopharma Inc|Sof daromad Innate Pharma S.A (IPHA)|Kompaniyaning sof foydasi Pyxis Oncology, Inc. (PYXS)|Sof daromad cgen.com CGEN|IO Biotech - Sof daromad|Sof foyda Sutro Biopharma Inc. STRO|INKT - Kompaniyaning sof foydasi|HOWL (Werewolf Therapeutics) - Kompaniya foydasi|immixbio.com (IMMX) - Kompaniyaning sof foydasi|Kompaniyaning sof daromadi alxoncology.com (ALXO)|Sof daromad CUE|PDSB - Yillik sof foyda|Sof daromad MAIA (MAIA Biotechnology Inc)|Soliqlar to‘langandan keyingi foyda LIMN|Sof foyda LVTX (LAVA Therapeutics)|Yakuniy foyda NXTC|Leap Tx - Sof foyda|Kompaniyaning sof daromadi Intensity Therapeutics|senseibio.com (SNSE) - Kompaniyaning sof foydasi|Theriva Corp - Yakuniy foyda|GRTS (Gritstone bio Inc.) - Sof foyda|Sof foyda kinetabio.com|Kompaniyaning sof foydasi NexImmune (NEXI)|TSBX: Soliqdan keyingi foyda|Vaccinex, Inc - Sof daromad|Harpoon Therapeutics Corp (HARP) - Kompaniyaning sof daromadi